WB-EMS Effects on Cardiometabolic Risk Factors
Condition(s) studied
Investigational drug(s) / intervention(s)
WB-EMS: 12 weeks of WB-EMS, 1.5x20 min/week
Control: 12 weeks without additional intervention and without life style changes
Study summary
From the age of 50 onwards, there is a disproportionate decline in muscle strength, mass and function, which can be prevented or at least delayed by physical training. Unfortunately, many training programmes are very time-consuming and strenuous and are therefore not carried out consistently. Whole-body electromyostimulation (WB-EMS), a technology in which all major muscle groups are stimulated with an adjusted stimulation level, could be a time-effective and joint-friendly alternative.
However, there are some contraindications to the widespread use of this technology, which are particularly common in middle-aged and elderly people. For example, high blood pressure, which affects more than half of men over the age of 50 in Germany, is considered a contraindication for WB-EMS training. However, this assessment is not very reliable; at least, acute WB-EMS application does not lead to an increase in blood pressure. In addition, there are no study results available for long-term WB-EMS application in people with high blood pressure.
The present study particularly investigate whether and to what extent several weeks of WB-EMS training has an effect on resting blood pressure in people with mild blood pressure. Additionally, the effect of WB-EMS on other cardiometabolic risk factors and physical function will be addressed.
Eligibility
Primary outcome measure(s)
- Resting blood pressure — At baseline and after 12 weeks of intervention
Changes of mean arterial blood pressure after 10 min of rest in a sitting position as assessed by an automatic sphygmomanometer - Metabolic syndrome — At baseline and after 12 weeks of intervention
Changes of the Metabolic Syndrome (MetS) as determined by the MetS-Z-Score
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| Faculty of Medicine, University of Tuebingen | Erlangen | Germany | |
| Institute of Radiology, University Hospital Erlangen | Erlangen | Germany |
More University of Erlangen-Nürnberg Medical School trials in Germany
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07406191 on ClinicalTrials.gov ↗ ← All trials in Germany